Publication

MRD4 eradication at 6 months and early clearance of MRD with combination of ibrutinib plus venetoclax results in sustained clinical and MRD responses: exploratory analysis of the Blood Cancer UK TAP Clarity Study

Munir, T.
; 
Cherrill, L. R.
; 
Webster, N.
; 
Dalal, S.
; 
Boucher, R. H.
; 
Sankhalpara, C.
; 
Yates, F.
; 
Fox, S.
; 
Macdonald, D.
; 
Fegan, C.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Munir, T.
Cherrill, L. R.
Webster, N.
Dalal, S.
Boucher, R. H.
Sankhalpara, C.
Yates, F.
Fox, S.
Macdonald, D.
Fegan, C.
McCaig, A.
Schuh, A.
Pettitt, A.
Gribben, J. G.
Patten, P. E. M.
Devereux, S.
Bloor, Adrian
Fox, C. P.
Forconi, F.
Rawstron, A. C.
Hillmen, P.
Affiliation
Department of Haematology, St James's University Hospital, Leeds,
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Munir T, Cherrill LR, Webster N, Dalal S, Boucher RH, Sankhalpara C, et al. MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study. Blood. 2022 Nov;140. PubMed PMID: WOS:000893223200092.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626105
Embedded videos